$25.83
+3.4%Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Last Annual Value
16.54M
3-Year CAGR
61%
5-Year CAGR
96%
10-Year CAGR
46%
| Company | Other Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Progyny, Inc. NASDAQ:PGNY | 16.54M | 69.5% | 41.2% | N/A | |
![]() Omada Health NASDAQ:OMDA | 8.88M | 7.8% | N/A | N/A | |
![]() 10x Genomics, Inc. NASDAQ:TXG | 2.91M | -1.6% | -23.2% | N/A | |
![]() Phreesia, Inc. NYSE:PHR | 108.94M | 179.1% | 130.6% | N/A | |
67.99M | -69.5% | -27.5% | -33.7% | ||
![]() GoodRx Holdings, Inc. NASDAQ:GDRX | 168.36M | 94.8% | 94.8% | N/A | |
![]() Omnicell, Inc. NASDAQ:OMCL | 123.04M | 24.1% | 5.5% | 13.4% | |
![]() Teladoc Health, Inc. NYSE:TDOC | 137.62M | 19.7% | 46.1% | 78.7% | |
![]() Schrödinger, Inc. NASDAQ:SDGR | 6.26M | 1.4% | 17.1% | N/A | |
![]() UFP Technologies, Inc. NASDAQ:UFPT | 10.91M | 23.5% | 15.0% | 1.3% |
Continue your PGNY research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.